Exploring the Breakthroughs in Early Alzheimer's Disease: Discussing Leqembi with a Prescriber & Examining the TRAILBLAZER-ALZ 2 Phase 3 Study ahead of Early 2024 PDUFA Decision

Executed on:Feb 22, 2024 2:30 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Washington University School of Medicine

Medical Director of the Memory Diagnostic Center and Director of the Knight ADRC Clinical Trials Unit team conducting clinical therapeutic trials for people with Alzheimer disease and other dementias at WUSTL.
Currently manages 300+ patients with memory disorder and roughly 200+ patients with Alzheimer disease.
Research focuses on the diagnosis and treatment of neurodegenerative disorders, specifically dementing disorders; Principal Investigator for numerous clinical therapeutic trials.

Interview Goal

This interview aims to delve into the groundbreaking results of the TRAILBLAZER-ALZ 2 Phase 3 study, focusing on donanemab's efficacy in significantly slowing cognitive and functional decline in early Alzheimer's disease. We will discuss the implications of these findings, the safety profile of donanemab, and its potential impact on the future of Alzheimer's disease treatment.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.